Greg Lipschitz, Executive Chairman of Firefly, said, “This breakthrough underscores our commitment to pushing the boundaries of innovation in brain health, ultimately with the aim of making a ...
Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...
Dementia is a devastating condition that can affect everything from your thinking to your personality. And while you can't always control your risk of developing the disease, new research finds ...